Skip to contentB
Boston Scientific Corp
B
BSXBoston Scientific Corp Source filing unavailable
Q3 2014 · —
Revenue$1.86B$1.86B+6.9% vs Q3 2013 Net Income$43.00M$43.00MN/M vs Q3 2013 EPS Diluted$0.03$0.03— vs Q3 2013 Gross Profit$1,296,000,000+5.8% Operating Income$64,000,000−37.9% Operating Cash Flowderived
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Boston Scientific Corp · CIK 885725 · Engraved from SEC EDGAR
$346,000,000
+37.8%
Free Cash Flowderived$290,000,000+49.5% Margins · derivedGross margin69.7%−0.7 pt vs Q3 2013
Operating margin3.4%−2.5 pt vs Q3 2013
Net margin2.3%+2.6 pt vs Q3 2013